Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes

J. Vora, S. C. Bain, T. Damci, G. Dzida, P. Hollander, L. F. Meneghini, S. A. Ross

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Incretin therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4Is) and GLP-1 receptor agonists (GLP-1RAs) have become well-established treatments for type 2 diabetes. Both drug classes reduce blood glucose through physiological pathways mediated by the GLP-1 receptor, resulting in glucose-dependent enhancement of residual insulin secretion and inhibition of glucagon secretion. In addition, the GLP-1RAs reduce gastrointestinal motility and appear to have appetite-suppressing actions and, so, are often able to produce clinically useful weight loss. The glucose-dependency of their glucagon-inhibiting and insulin-enhancing effects, together with their weight-sparing properties, make the incretin therapies a logical proposition for use in combination with exogenous basal insulin therapy. This combination offers the prospect of an additive or synergistic glucose-lowering effect without a greatly elevated risk of hypoglycaemia compared with insulin monotherapy, and any insulin-associated weight gain might also be mitigated. Furthermore, the incretin therapies can be combined with metformin, which is usually continued when basal insulin is introduced in type 2 diabetes. Although the combination of incretin and insulin therapy is currently not addressed in internationally recognized treatment guidelines, several clinical studies have assessed its use. The data, summarized in this review, are encouraging and show that glycaemic control is improved and weight gain is limited or reversed (especially with the combined use of GLP-1RAs and basal insulin), and that the use of an incretin therapy can also greatly reduce insulin dose requirements. The addition of basal insulin to established incretin therapy is straightforward, but insulin dose adjustment (though not discontinuation) is usually necessary if the sequence is reversed.

Original languageEnglish
Pages (from-to)6-15
Number of pages10
JournalDiabetes and Metabolism
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Incretins
Type 2 Diabetes Mellitus
Insulin
Therapeutics
Glucagon
Glucose
Weight Gain
Dipeptidyl-Peptidase IV Inhibitors
Social Adjustment
Gastrointestinal Motility
Metformin
Appetite
Hypoglycemia
Blood Glucose
Weight Loss

Keywords

  • DPP-IV inhibitors
  • GLP-1 analogue
  • HbA
  • Insulin
  • Review
  • Type 2 diabetes mellitus
  • Weight

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Incretin-based therapy in combination with basal insulin : A promising tactic for the treatment of type 2 diabetes. / Vora, J.; Bain, S. C.; Damci, T.; Dzida, G.; Hollander, P.; Meneghini, L. F.; Ross, S. A.

In: Diabetes and Metabolism, Vol. 39, No. 1, 01.01.2013, p. 6-15.

Research output: Contribution to journalArticle

Vora, J. ; Bain, S. C. ; Damci, T. ; Dzida, G. ; Hollander, P. ; Meneghini, L. F. ; Ross, S. A. / Incretin-based therapy in combination with basal insulin : A promising tactic for the treatment of type 2 diabetes. In: Diabetes and Metabolism. 2013 ; Vol. 39, No. 1. pp. 6-15.
@article{b703e0ddd3d14d2bbe20fb7844da9751,
title = "Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes",
abstract = "Incretin therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4Is) and GLP-1 receptor agonists (GLP-1RAs) have become well-established treatments for type 2 diabetes. Both drug classes reduce blood glucose through physiological pathways mediated by the GLP-1 receptor, resulting in glucose-dependent enhancement of residual insulin secretion and inhibition of glucagon secretion. In addition, the GLP-1RAs reduce gastrointestinal motility and appear to have appetite-suppressing actions and, so, are often able to produce clinically useful weight loss. The glucose-dependency of their glucagon-inhibiting and insulin-enhancing effects, together with their weight-sparing properties, make the incretin therapies a logical proposition for use in combination with exogenous basal insulin therapy. This combination offers the prospect of an additive or synergistic glucose-lowering effect without a greatly elevated risk of hypoglycaemia compared with insulin monotherapy, and any insulin-associated weight gain might also be mitigated. Furthermore, the incretin therapies can be combined with metformin, which is usually continued when basal insulin is introduced in type 2 diabetes. Although the combination of incretin and insulin therapy is currently not addressed in internationally recognized treatment guidelines, several clinical studies have assessed its use. The data, summarized in this review, are encouraging and show that glycaemic control is improved and weight gain is limited or reversed (especially with the combined use of GLP-1RAs and basal insulin), and that the use of an incretin therapy can also greatly reduce insulin dose requirements. The addition of basal insulin to established incretin therapy is straightforward, but insulin dose adjustment (though not discontinuation) is usually necessary if the sequence is reversed.",
keywords = "DPP-IV inhibitors, GLP-1 analogue, HbA, Insulin, Review, Type 2 diabetes mellitus, Weight",
author = "J. Vora and Bain, {S. C.} and T. Damci and G. Dzida and P. Hollander and Meneghini, {L. F.} and Ross, {S. A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.diabet.2012.08.002",
language = "English",
volume = "39",
pages = "6--15",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "1",

}

TY - JOUR

T1 - Incretin-based therapy in combination with basal insulin

T2 - A promising tactic for the treatment of type 2 diabetes

AU - Vora, J.

AU - Bain, S. C.

AU - Damci, T.

AU - Dzida, G.

AU - Hollander, P.

AU - Meneghini, L. F.

AU - Ross, S. A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Incretin therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4Is) and GLP-1 receptor agonists (GLP-1RAs) have become well-established treatments for type 2 diabetes. Both drug classes reduce blood glucose through physiological pathways mediated by the GLP-1 receptor, resulting in glucose-dependent enhancement of residual insulin secretion and inhibition of glucagon secretion. In addition, the GLP-1RAs reduce gastrointestinal motility and appear to have appetite-suppressing actions and, so, are often able to produce clinically useful weight loss. The glucose-dependency of their glucagon-inhibiting and insulin-enhancing effects, together with their weight-sparing properties, make the incretin therapies a logical proposition for use in combination with exogenous basal insulin therapy. This combination offers the prospect of an additive or synergistic glucose-lowering effect without a greatly elevated risk of hypoglycaemia compared with insulin monotherapy, and any insulin-associated weight gain might also be mitigated. Furthermore, the incretin therapies can be combined with metformin, which is usually continued when basal insulin is introduced in type 2 diabetes. Although the combination of incretin and insulin therapy is currently not addressed in internationally recognized treatment guidelines, several clinical studies have assessed its use. The data, summarized in this review, are encouraging and show that glycaemic control is improved and weight gain is limited or reversed (especially with the combined use of GLP-1RAs and basal insulin), and that the use of an incretin therapy can also greatly reduce insulin dose requirements. The addition of basal insulin to established incretin therapy is straightforward, but insulin dose adjustment (though not discontinuation) is usually necessary if the sequence is reversed.

AB - Incretin therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4Is) and GLP-1 receptor agonists (GLP-1RAs) have become well-established treatments for type 2 diabetes. Both drug classes reduce blood glucose through physiological pathways mediated by the GLP-1 receptor, resulting in glucose-dependent enhancement of residual insulin secretion and inhibition of glucagon secretion. In addition, the GLP-1RAs reduce gastrointestinal motility and appear to have appetite-suppressing actions and, so, are often able to produce clinically useful weight loss. The glucose-dependency of their glucagon-inhibiting and insulin-enhancing effects, together with their weight-sparing properties, make the incretin therapies a logical proposition for use in combination with exogenous basal insulin therapy. This combination offers the prospect of an additive or synergistic glucose-lowering effect without a greatly elevated risk of hypoglycaemia compared with insulin monotherapy, and any insulin-associated weight gain might also be mitigated. Furthermore, the incretin therapies can be combined with metformin, which is usually continued when basal insulin is introduced in type 2 diabetes. Although the combination of incretin and insulin therapy is currently not addressed in internationally recognized treatment guidelines, several clinical studies have assessed its use. The data, summarized in this review, are encouraging and show that glycaemic control is improved and weight gain is limited or reversed (especially with the combined use of GLP-1RAs and basal insulin), and that the use of an incretin therapy can also greatly reduce insulin dose requirements. The addition of basal insulin to established incretin therapy is straightforward, but insulin dose adjustment (though not discontinuation) is usually necessary if the sequence is reversed.

KW - DPP-IV inhibitors

KW - GLP-1 analogue

KW - HbA

KW - Insulin

KW - Review

KW - Type 2 diabetes mellitus

KW - Weight

UR - http://www.scopus.com/inward/record.url?scp=84874288415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874288415&partnerID=8YFLogxK

U2 - 10.1016/j.diabet.2012.08.002

DO - 10.1016/j.diabet.2012.08.002

M3 - Article

C2 - 23022130

AN - SCOPUS:84874288415

VL - 39

SP - 6

EP - 15

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 1

ER -